AbbVie Inc. (NYSE:ABBV) Shares Acquired by Schulhoff & Co. Inc.

Schulhoff & Co. Inc. lifted its holdings in shares of AbbVie Inc. (NYSE:ABBVGet Rating) by 0.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 33,138 shares of the company’s stock after buying an additional 200 shares during the period. AbbVie makes up about 1.8% of Schulhoff & Co. Inc.’s portfolio, making the stock its 17th biggest holding. Schulhoff & Co. Inc.’s holdings in AbbVie were worth $4,486,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. Marino Stram & Associates LLC lifted its holdings in AbbVie by 3.5% in the 4th quarter. Marino Stram & Associates LLC now owns 12,718 shares of the company’s stock worth $1,722,000 after buying an additional 431 shares in the last quarter. PSI Advisors LLC lifted its holdings in AbbVie by 9.0% in the 3rd quarter. PSI Advisors LLC now owns 26,001 shares of the company’s stock worth $2,805,000 after buying an additional 2,140 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in AbbVie by 237.7% in the 4th quarter. International Assets Investment Management LLC now owns 185,150 shares of the company’s stock worth $1,696,000 after buying an additional 130,327 shares in the last quarter. Clark Capital Management Group Inc. lifted its holdings in AbbVie by 49.3% in the 3rd quarter. Clark Capital Management Group Inc. now owns 364,231 shares of the company’s stock worth $39,290,000 after buying an additional 120,309 shares in the last quarter. Finally, Edmonds Duncan Registered Investment Advisors LLC acquired a new position in AbbVie in the 4th quarter worth $223,000. Institutional investors and hedge funds own 65.62% of the company’s stock.

In other news, VP Brian L. Durkin sold 18,628 shares of the company’s stock in a transaction that occurred on Wednesday, March 9th. The shares were sold at an average price of $150.01, for a total value of $2,794,386.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Vice Chairman Robert A. Michael sold 43,105 shares of the company’s stock in a transaction that occurred on Tuesday, March 1st. The stock was sold at an average price of $148.25, for a total transaction of $6,390,316.25. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 106,819 shares of company stock valued at $16,155,094. Company insiders own 0.08% of the company’s stock.

Several equities research analysts have recently weighed in on the stock. Mizuho boosted their target price on shares of AbbVie from $154.00 to $166.00 and gave the stock a “buy” rating in a research report on Friday, February 4th. JPMorgan Chase & Co. boosted their target price on shares of AbbVie from $165.00 to $180.00 in a research report on Thursday, February 3rd. The Goldman Sachs Group boosted their target price on shares of AbbVie from $122.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. StockNews.com raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 8th. Finally, Redburn Partners assumed coverage on shares of AbbVie in a research report on Thursday, January 13th. They issued a “buy” rating for the company. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $157.73.

NYSE ABBV traded down $9.43 on Friday, hitting $146.88. The stock had a trading volume of 25,155,901 shares, compared to its average volume of 7,748,779. AbbVie Inc. has a one year low of $105.56 and a one year high of $175.91. The company has a quick ratio of 0.70, a current ratio of 0.79 and a debt-to-equity ratio of 4.16. The stock has a market cap of $259.43 billion, a price-to-earnings ratio of 22.77, a P/E/G ratio of 4.40 and a beta of 0.81. The company’s 50-day moving average is $157.06 and its two-hundred day moving average is $137.25.

AbbVie (NYSE:ABBVGet Rating) last posted its earnings results on Friday, April 29th. The company reported $3.16 EPS for the quarter, topping the consensus estimate of $3.14 by $0.02. AbbVie had a net margin of 20.54% and a return on equity of 164.05%. The firm had revenue of $13.36 billion during the quarter, compared to analysts’ expectations of $13.61 billion. During the same quarter in the prior year, the firm earned $2.95 EPS. AbbVie’s quarterly revenue was up 2.7% on a year-over-year basis. On average, sell-side analysts anticipate that AbbVie Inc. will post 14.11 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, May 16th. Stockholders of record on Friday, April 15th will be paid a $1.41 dividend. This represents a $5.64 dividend on an annualized basis and a dividend yield of 3.84%. The ex-dividend date of this dividend is Wednesday, April 13th. AbbVie’s dividend payout ratio is currently 87.44%.

About AbbVie (Get Rating)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Further Reading

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVGet Rating).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.